Validation of a Novel Treatment for Glioblastoma

胶质母细胞瘤新疗法的验证

• 批准号: 8833152
• 负责人: Santosh Kesari
• 金额: $ 22.5万
• 依托单位: CURTANA PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-24 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8833152
• 关键词: Adjuvant; Affect; Animal Model; Area; Blood - brain barrier anatomy; Brain; CDK2 gene; CDK4 gene; Cancer Center; Cells; Chemosensitization; Data; Disease; Drug Discovery Groups; Drug Formulations; EGF gene; Evaluation; Feasibility Studies; Fund Raising; Glioblastoma; Goals; Heat-Shock Proteins 90; In Vitro; Literature; Medical; Modeling; Molecular; Mus; Outcome; Pathology; Pathway interactions; Patients; Penetration; Permeability; Pharmacologic Substance; Pharmacotherapy; Phase; Plasma; Platelet-Derived Growth Factor; Protein Kinase; Proteins; Protocols documentation; Publishing; Radiation; Radiation therapy; Radio; Radiosensitization; Rationalization; Route; Sampling; Series; Small Business Technology Transfer Research; Testing; Therapeutic; Validation; Work; analog; base; chemotherapy; experience; in vitro Model; in vitro activity; in vivo; in vivo Model; inhibitor/antagonist; mortality; novel; pre-clinical; public health relevance; research clinical testing; small molecule; standard of care; stem; temozolomide; transcription factor

 DESCRIPTION (provided by applicant): The goal of this application is to study in vivo efficacy of CT102, a newly discovered inhibitor of the OLIG2 transcription factor in animal models of glioblastoma (GBM), a highly underserved area of pharmacotherapy. In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity and in vivo distribution of CT102 to determine protocols for efficacy studies in orthotopic models of GBM. CT102 will be studied at UCSD to confirm potency of newly synthesized materials, assess activity in an orthotopic model of GBM and conduct in vitro and in vivo profiling to evaluate CT102 as a sensitizer to chemo- or radiotherapy. A successful outcome may result in a potential small molecule therapeutic for GBM.

 描述（通过应用程序提供）：本应用的目的是研究CT102的体内效率，CT102是胶质母细胞瘤（GBM）动物模型的新发现的Olig2转录因子的抑制剂，这是药物疗法的高度不足的区域。 In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity and in vivo distribution of CT102 to determine protocols for CT102 will be studied at UCSD to confirm potency of newly synthesized materials, assessment activity in an orthotopic model of GBM and conduct in vitro and in vivo profiling to evaluate CT102 as a sensor to chemo- or放疗。成功的结果可能会导致GBM潜在的小分子治疗。